Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 

Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Current Award

Photo Pending

Catherine Clelland, Ph.D.

Columbia University
New York, NY

Title: The Role of miR-138 in Alzheimer’s Disease Dendritic Spine Pathology
Non-Technical Title: Exploring a novel abnormal regulatory pathway in Alzheimer’s disease brain cell connections

Duration: April 1, 2010 - March 31, 2012
Award Type: Pilot
Award Amount: $150,000


Summary:

We will test if dysregulation of the miR-138 controlled pathway contributes to dendritic spine pathology in a murine tauopathy model. We believe this project is highly innovative because if successful, this study will be one of the first to directly link the dysregulation of a miRNA regulated pathway to the in vivo dendritic spine pathology seen in a mouse model of human tauopathy.

Details:

We are going to investigate the role of an important class of regulatory proteins in Alzheimer’s disease. The success of this project may be beneficial to the public in the form of new treatment developments.